Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • New Pharma Policy...

    New Pharma Policy approved in Haryana, to generate 25000 new jobs

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 5 Feb 2019 5:23 AM  |  Updated On 5 Feb 2019 5:23 AM
    New Pharma Policy approved in Haryana, to generate 25000 new jobs

    Haryana: Aiming to attract investment in the pharmaceutical sector to the tune of Rs 2,000 crore and to generate 25,000 new jobs, the Haryana Cabinet which met here on Monday under the chairmanship of Chief Minister Manohar Lal approved the Haryana Pharmaceutical Policy 2019.


    The policy envisages to establish a state-of-the-art Pharma Park at Karnal and to develop Haryana into a hub for pharmaceutical manufacturing by facilitating and creating a holistic industry, academia, and research and development (R&D) ecosystem.


    The objective of the policy is to implement an enabling regulatory environment for the pharmaceutical sector, with investor friendly and time-bound clearance delivery system, focus on holistic pharmaceutical cluster development, provide fiscal and non-fiscal benefits to units setting up in the Pharma Park, in a dedicated and streamlined manner, develop quality industrial infrastructure to support entrepreneurs in the State, provide land at subsidised rates to entrepreneurs for establishing Pharma units and effectively utilise the Single Window clearance mechanism, providing clearances in a time-bound manner.


    According to an official statement, fiscal incentives for new units will be applicable as per investment category, as mentioned in the Haryana Enterprises Promotion Policy 2015. In addition to incentives offered under the Haryana Enterprises Promotion Policy 2015, all new units in the Pharma Parks in the State will be eligible for a special package of incentives.


    These included reimbursement of 25 per cent of cost of plant and machinery subject to a maximum of Rs 50 lakh and interest subsidy to the extent of 5 per cent per annum for five years in the form of reimbursement of interest paid on loan taken to meet the working capital requirements, subject to annual ceiling of Rs 25 lakh per annum per unit.


    In order to simplify the regulatory processes for new investors in the pharma industry in Haryana, the state government will integrate all pharma sector related clearances with the Single Window portal of the State that is HEPC (Invest Haryana- www.investharyana.in), to provide clearances in a time-bound, completely online, and streamlined manner.


    The state government will grant approval to all rational drugs which have been approved by neighbouring state licensing authorities and declared rational by the expert committees constituted by Government of India and which are not banned or prohibited by Government of India under Section 26-A of Drugs Act.


    Also Read: Make in India in the Pharmaceutical sector: Government prefers domestic drugs for public procurement

    DOPDrugs Actgovt of indiaHaryana CabinetHaryana CMHaryana Enterprises Promotion Policyindian govtNew pharma policyPharma News in Haryanapharma parkpharma sectorpharmaceuticalPharmaceutical policyR&Dwww.investharyana.in
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok